BioMedNewsBreaks

MondaySep 28, 2020 11:54 am

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Equity Research Company Update

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in an Equity Research Company Update by Maxim Group LLC. The report, titled “Benzo-Benefits Without the Benzo-Baggage – The Case for PH94B Builds,” highlights potential benefits of VistaGen’s PH94B drug candidate, a nasal spray designed for treatment of adults with social anxiety disorder, as compared to treatment with benzodiazepines. The report reads, “Benzodiazepines (benzos) have been available to treat anxiety since the 1960s, and include well-known products such as Xanax, Ativan, and Klonopin. These drug compounds work…

Continue Reading

FridaySep 25, 2020 2:45 pm

BioMedNewsBreaks – 180 Life Sciences Corp. Advancing Lead Program, Plans Additional Clinical Trials

180 Life Sciences, a clinical-stage biotechnology company, is dedicated to producing solutions designed to battle inflammation when the body’s natural processes go awry. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, designed to block the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases. The company is advancing on this front as discussed by a recent article that reads, “180 Life Sciences’ lead program is in phase 2b/3 clinical trials and expects to deliver its first results next year. Other clinical trials planned by the company are…

Continue Reading

ThursdaySep 24, 2020 12:58 pm

BioMedNewsBreaks – Humanigen Inc. (NASDAQ: HGEN) Secures $78.2M in Underwritten Public Offering

Humanigen (NASDAQ: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab, has closed an underwritten public offering of 9,200,000 shares of common stock, including 1,200,000 shares pursuant to the full exercise of the over-allotment option granted to the underwriters. According to the update, Humanigen secured approximately $78.2 million in gross proceeds, with each of the shares sold at the public offering price of $8.50. The company intends to use the proceeds to support its manufacturing, production and commercial preparation activities relating to lenzilumab as a potential therapy…

Continue Reading

ThursdaySep 24, 2020 11:04 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Partners with Leading Medical Imaging Group for Upcoming Berubicin Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has announced that it will partner with Image Analysis Group (“IAG”) for planned Berubicin clinical trials. IAG, a leading medical imaging group, and CNS will work together to provide critical imaging services and imaging data analysis for the trials. IAG has an extensive background of partnering with oncology companies to deliver centralized readings and analysis of patient responses in real time. IAG’s expertise will allow CNS to review efficacy assessments and explore the advanced-treatment manifestations. Because…

Continue Reading

WednesdaySep 23, 2020 9:45 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Granted License for Additional 71 Unique Ovarian Cancer Cell Lines

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, a division of the company, has received a license for an additional 71 unique ovarian cancer call lines. The licensing comes from England-based Ximbio, the largest nonprofit in the world dedicated to life science reagents. TumorGenesis now has a total of 96 unique patient-derived ovarian cancer cell lines. Research such as that conducted by TumorGenesis is  the foundation of preclinical research and development. “It is remarkable that the UK cancer researchers using the same media mixes now…

Continue Reading

TuesdaySep 22, 2020 5:03 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP), Sub-Licensee Partner Advancing Lead Drug Candidate in First-Ever Phase 1 and Phase 2 Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing its leading drug candidate, Berubicin, to move forward with clinical trials in Poland. This move comes after sub-licensee WPD Pharmaceuticals Inc. has identified a contract research organization — Worldwide Clinical Trials — to coordinate and supervise Phase 1 and Phase 2 trials in the European country (http://ibn.fm/iFYph). A recent article discussing this reads, “Berubicin is proposed for the treatment of glioblastoma multiforme (‘GBM’), an aggressive and incurable form of brain cancer. Berubicin also…

Continue Reading

MondaySep 21, 2020 2:11 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) and HMC HealthWorks Enter Sales and Distribution Partnership

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, together with HMC HealthWorks, a 40-year veteran in health-care management with clinically-integrated models of care that reduce health-care costs and improve population health, today announced entry into a sales and distribution agreement. Under the partnership, HMC will incorporate DarioHealth's digital therapeutics solution into its care management programs on a stand-alone basis as well as for incorporation within HMC’s comprehensive solutions. "We believe that this agreement with HMC is further validation of the progress we have made in transitioning to a leading provider of digital-therapeutics solutions to payors, employers and other…

Continue Reading

MondaySep 21, 2020 1:24 pm

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Appoints Seasoned Biotech Executive to Advance Expanding IP Estate

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced it has named Thomas C. Gallagher, Esq. as its senior vice president of Intellectual Property and Licensing. According to the update, Gallagher has extensive experience in the area of biotechnology intellectual property (“IP”) law, business development and licensing transactions with industry and academic institutions. “Mr. Gallagher will play a critical role in advancing our expanding intellectual property estate by spearheading IP strategy, which is an important element of the company’s overall success and value creation,” said Genprex president and CEO…

Continue Reading

MondaySep 21, 2020 11:10 am

BioMedNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Announces Engagement of Tailwinds Research Group, Video Update and Strategic Advisory Board Appointment

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, on Friday announced its engagement of Tailwinds Research Group to provide digital content distribution for the company. According to the update, the engagement will cover a 1-year term, at US$2,500/month with 100,000 stock options provided at C$0.88/option. In addition, LexaGene today released a video message from its founder and CEO, Dr. Jack Regan, that highlighted the company’s progress toward commercial sales and announced the appointment of Dr. Shelley Rankin to LexaGene’s Scientific Advisory Board. “As we approach sales, I’m very pleased to…

Continue Reading

FridaySep 18, 2020 1:12 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Helomics Provide Key Insight to Personalized Cancer Treatment

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, lives by the motto: Cancer is personal; we believe therapy should be too. The company’s subsidiary Helomics builds AI-driven models designed to predict drug response and patient outcome of individual tumors. The company is able to do that because it relies on POAI’s tumor inventory, one of the largest in the world. POAI is a leader in working with oncologists in offering a functional precision medicine approach to treating cancer. Key information provided by Predictive Oncology can improve a patient’s odds in the fight against…

Continue Reading